Hit enter to search or ESC to close

Transforming the way we protect those who protect us.

Bio Defense

The NCBiotech Bio Defense program expands the life science base of North Carolina’s $38 billion defense economy.

Our Bio Defense outreach goes far beyond concerns over bioterrorism. NCBiotech and partners -- North Carolina’s small companies, researchers and military representatives -- are thinking more broadly. We work to provide vaccines for soldiers, to protect the food supply, and to find how best to deploy novel technologies that will protect our soldiers and heal those who sustain wounds in battle.

Statistics

12

percent of NC's GDP is military

540,000+

total jobs supported

$66B

total economic impact in NC

$1.9B

provided by Department of Veterans Affairs in medical care to NC

6

major military installations

Given the size and significance of the federal investments in NC, NCBiotech and partners are working to bring the state’s innovative, life science technological expertise to bear to address critical challenges faced by the military and national security agencies. Developing strategies to better align the state’s well-recognized life science strengths with the Department of Defense (DoD) and national security strategic priorities will enable our state to be a critical solution provider on challenging problems while also increasing defense funding to support North Carolina researchers and companies.

Some of these NCBiotech-led activities include:

Providing support for university-based researchers and small businesses that have a technology that addresses a need in the Bio Defense arena and educate and support their efforts in seeking DoD or homeland security relationships and funding
Promoting and representing North Carolina at targeted military and federal Bio Defense conferences throughout the United States and promote our state's life science capabilities
Hosting or sponsoring conferences where military, government, academic and industry experts can network and collaborate
Connecting military, industry and academia partners to promote North Carolina’s Bio Defense capabilities at the state and federal level

For additional information, please see our Bio Defense Initiative one-pager.

Business North Carolina magazine, with the help from the North Carolina Biotechnology Center, held a roundtable of distinguished experts discussing opportunities for growing the bio defense sector in N.C.

Bio Defense News & Events

CARB-X 2018 Event Presentation

CARB-X is the world’s largest-public-private partnership devoted to early development antibacterial R&D. CARB-X has announced the opening of its 2018 funding cycle to support the early development of antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria.

For further information, please refer to the CARB-X press release and website.

View the event presentation and video from March 9 held at NCBiotech:

Presentation: CARB-X 2018 Funding Rounds, Kevin Outterson, Executive Director, CARB-X during the CARB-X Funding Information Session Event.
Video: CARB-X Funding Information Session Event

United States Army Medical and Materiel Command (USAMRMC)

The United States Army Medical and Materiel Command's (USAMRMC) mission is to provide solutions to medical problems of importance to the American Service member at home and abroad, as well as to the general public at large. Extramural research and development programs play a vital role in the fulfillment of the objectives established by the USAMRMC.

The FY18-FY22 USAMRMC Broad Agency Announcement (BAA) is intended to solicit extramural research and development ideas. Research and development funded through the BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge.
Read more information.

Biodefense Advanced Research and Development Authority (BARDA)

The Biodefense Advanced Research and Development Authority (BARDA) released its 2018 BARDA Broad Agency Announcement (BAA), soliciting proposals for advanced research and development of medical countermeasures (MCM). BARDA seeks proposals to detect, contain, and treat chemical, biological, radiological, and nuclear (CBRN) agents; pandemic influenza; and emerging infectious diseases. The BAA highlights areas of interest, which include various technologies, vaccines, therapeutics, diagnostics, and devices to address these threats and to protect U.S. civilian health.

BARDA’s mission “is to develop and procure medical countermeasures that address the public health and medical consequences of CBRN accidents, incidents and attacks; pandemic influenza; and emerging infectious diseases.” BARDA’s priorities and programs closely align with the Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Strategic Plan, as well as the Department of Health and Human Services (HHS) Pandemic Influenza Plan and other interagency efforts to promote and protect the nation’s public health. Per the BAA, interested applicants should be aware of these efforts and agencies’ roles in the national MCM enterprise.

Application Deadline:

Stage One (quad charts and white papers) – January 31, April 30, July 31, and October 31, in both 2018 and 2019
Invited full proposals are due any day during the open period for the BAA (i.e., through October 31, 2019)

Total Funding and Award Size: BARDA anticipates issuing multiple awards of various sizes. Total available funding is subject to change depending on budget and emerging priorities.

Eligibility: The BAA is open to all “single entities or teams from private sector organizations, government laboratories, and academic institutions.” Those interested are encouraged to verify the BAA for full eligibility requirements and award restrictions.

For questions or more information, contact:
Mary Beth Thomas, Ph.D.
Vice President, Emerging Sector Development

Emerging Sector Development

| 919-549-8844 | marybeth_thomas@ncbiotech.org